India, Oct. 13 -- Immutep Ltd. (IMMP), an immunotherapy company targeting cancer and autoimmune diseases, announced it received a written notification from the Nasdaq confirming it has regained compliance with the minimum bid price requirement.
To address the deficiency, the company changed the American Depositary Share(ADS)-to-ordinary share ratio from one ADS representing 10 ordinary shares to one ADS representing 200 ordinary shares, effective 28 September 2026.
According to the notice, Nasdaq determined that the closing bid price of the company's American Depositary Shares was at or above $1.00 per ADS for 10 consecutive business days, from 28 September 2026 to 9 October 2026.
The company's ADSs continue to trade on the Nasdaq Global...